Treatment of hepatitis E virus

Current Opinion in Infectious Diseases

Volumn 29, Issue 6, 2016, Pages 639-644

  Dalton, Harry R ^a   Kamar, Nassim ^b  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Hepatitis E virus; Ribavirin; Viral mutation; Zoonosis

Indexed keywords

DACLATASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ACUTE HEPATITIS; ANTIVIRAL THERAPY; DRUG MECHANISM; GRAFT RECIPIENT; HEPATITIS E; HEPATITIS E VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; NEUROLOGIC DISEASE; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS MUTATION; ANIMAL; GENETICS; GENOTYPE; IMMUNOCOMPROMISED PATIENT; PIG;

ANIMALS; ANTIVIRAL AGENTS; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; RIBAVIRIN; SWINE;

EID: 84986215081     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000316     Document Type: Review

References (24)

1. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev 2014; 27: 116-138.
2. Blasco-Perrin H, Madden RG, Stanley A, et al. Hepatitis E virus in patients with decompensated chronic liver disease: A prospective UK/French study. Aliment Pharmacol Ther 2015; 42: 574-581.
3. Hogema BM, Molier M, Sjerps M, et al. Incidence and duration of hepatitis E virus infection in Dutch blood donors. Transfusion 2016; 56: 722-728.
4. Perumpail RB, Ahmed A, Higgins JP, et al. Fatal accelerated cirrhosis after imported HEV genotype 4 infection. Emerg Infect Dis 2015; 21: 1679-1681.
5. Pé ron JM, Abravanel F, Guillaume M, et al. Treatment of autochthonous acute hepatitis E with short-term ribavirin: A multicenter retrospective study. Liver Int 2016; 36: 328-333.
6. Tavitian S, Peron JM, Huguet F, et al. Ribavirin for chronic hepatitis prevention among patients with hematologic malignancies. Emerg Infect Dis 2015; 21: 1466-1469.
7. Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370: 1111-1120.
8. Abravanel F, Lhomme S, Rostaing L, et al. Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. Clin Infect Dis 2015; 60: 96-99.
9. Kamar N, Lhomme S, Abravanel F, et al. An early viral response predicts the virological response to ribavirin in hepatitis E virus organ transplant patients. Transplantation 2015; 99: 2124-2131.
10. Woolson KL, Forbes A, Vine L, et al. Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther 2014; 40: 1282-1291.
11. Kamar N, Weclawiack H, Guilbeaud-Frugier C, et al. Hepatitis E virus and the kidney in solid-organ-transplant patients. Transplantation 2012; 93: 617-623.
12. Del Bello A, Guilbeau-Frugier C, Josse AG, et al. Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin. Transpl Infect Dis 2015; 17: 279-283.
13. van den Berg B, van der Eijk AA, Pas SD, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology 2014; 82: 491-497.
14. van Eijk JJ, Madden RG, van der Eijk AA, et al. Neuralgic amyotrophy and hepatitis E virus infection. Neurology 2014; 82: 498-503.
15. Dalton HR, Kamar N, van Eijk JJ, et al. Hepatitis E virus and neurological injury. Nat Rev Neurol 2016; 12: 77-85.
16. Dalton HR, Keane FE, Bendall R, et al. Treatment of chronic hepatitis E in a patient with HIV infection. Ann Intern Med 2011; 155: 479-480.
17. Debing Y, Emerson SU, Wang Y, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother 2014; 58: 267-273.
18. Wang Y, Zhou X, Debing Y, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 2014; 146: 1775-1783.
19. Todt D, Gisa A, Radonic A, et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut 2016; pii: Gutjnl-2015-311000. [Epub ahead of print]
20. Debing Y, Gisa A, Dallmeier K, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure inorgantransplant recipients.Gastroenterology2014;147: 1008-1011.
21. Lhomme S, Kamar N, Nicot F, et al. Mutation in the hepatitis E virus polymerase and outcome of ribavirin therapy. Antimicrob Agents Chemother 2015; 60: 1608-1614.
22. Debing Y, Ramiere C, Dallmeier K, et al. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. J Hepatol 2016; 65: 499-508.
23. Dao Thi VL, Debing Y, Wu X, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 2016; 150: 82-85.
24. Donnelly M, Simpson K, Abravanel F, et al. Sofosbuvir and daclatasvir antiviral therapy fails to clear HEV viremia and restore reactive T cells in a HEV/HCV co-infected liver transplant recipient. Gastroenterology 2016. (In press).